Administering HIV medication to people suffering from visceral leishmaniasis is a very complicated process, especially in the developing world. For these individuals, experts have created a new drug delivery system, which is currently about to start further clinical development.
The system – which is used to deliver the drug Amphotericin B (Amp B) – was developed by professors Kishor and Ellen Wasanm, who are both based at the University of British Columbia's (UBC) Pharmaceutical Sciences.
Experts from the Neglected Global Diseases initiative also collaborated for this effort. The drug delivery system is currently licensed to iCo Therapeutics Inc. Experts now want to improve this approach, and have just been awarded a $1.1 grant from the National Research Council of Canada.
What Oral Amp B does is force HIV to move out of the persistent reservoirs that it occupies in the body, and which allow it to persist and endure the effects of HAART. By flushing the viruses out of cover, Oral Amp B allows HAART to kill them off, potentially opening the way to eradicating HIV.
“We are excited about the potential that oral Amp B may have as a treatment for HIV and thank the National Research Council of Canada and iCo Therapeutics for supporting this important technology,” explains Kishor Wasan.
“This funding represents a significant leap forward in the clinical development of the oral formulation of Amp B,” adds the expert, who holds an appointment as a professor and associate dean of research and graduate studies with the UBC Faculty of Pharmaceutical Sciences.
“The development of the Oral Amp B technology has profound implications in the quest to find a cure for HIV. We are looking forward to collaborating with UBC and NRC-IRAP on this program and the continued development of the Oral Amp B system,” iCo Therapeutics CEO and President, Andrew Rae, concludes.
Via: New Drug Against HIV Enters Clinical Development
Tidak ada komentar:
Posting Komentar